Effect of Gut Dysbiosis on Onset of GI Cancer DOI Open Access
Seema Kumari, Mundla Srilatha, Ganji Purnachandra Nagaraju

et al.

Cancers, Journal Year: 2024, Volume and Issue: 17(1), P. 90 - 90

Published: Dec. 30, 2024

Dysbiosis in the gut microbiota plays a significant role GI cancer development by influencing immune function and disrupting metabolic functions. can drive carcinogenesis through pathways like dysregulation release of carcinogenic metabolites, altered metabolism, genetic instability, pro-inflammatory signalling, contributing to initiation progression. Helicobacter pylori infection genotoxins released from dysbiosis, lifestyle dietary habits are other factors that contribute development. Emerging diagnostic therapeutic approaches show promise colorectal treatment, including multitarget faecal immunochemical test (mtFIT), standard FIT, transplantation (FMT) combined with PD-1 inhibitors. We used search engine databases PubMed, Scopus, Web Science. This review discusses dysbiosis onset explores strategies such as FMT, probiotics, prebiotics enhance response improve therapy outcomes.

Language: Английский

Dysbiosis–NK Cell Crosstalk in Pancreatic Cancer: Toward a Unified Biomarker Signature for Improved Clinical Outcomes DOI Open Access
Sara Fanijavadi, Lars Henrik Jensen

International Journal of Molecular Sciences, Journal Year: 2025, Volume and Issue: 26(2), P. 730 - 730

Published: Jan. 16, 2025

Pancreatic ductal adenocarcinoma (PDAC) is an aggressive cancer with poor prognosis, primarily due to its immunosuppressive tumor microenvironment (TME), which contributes treatment resistance. Recent research shows that the microbiome, including microbial communities in oral cavity, gut, bile duct, and intratumoral environments, plays a key role PDAC development, imbalances (dysbiosis) promoting inflammation, progression, therapy resistance, side effects. Microbial metabolites can also affect immune cells, especially natural killer (NK) are vital for surveillance, response treatment-related Dysbiosis NK cell function, leading resistance We propose combined biomarker approach, integrating microbiome composition profiles, help predict effects, enabling more personalized therapies. This review examines how dysbiosis dysfunction discusses strategies (e.g., antibiotics, probiotics, vaccines) modulate enhance function. Targeting could activity, improve effectiveness of treatments, reduce However, further needed develop unified cell–microbiome interaction-based biomarkers precise effective patient outcomes.

Language: Английский

Citations

1
Regulatory role of gut microbiota in immunotherapy of hepatocellular carcinoma DOI

Jiajia Du,

Yan Guan,

Erlei Zhang

et al.

Hepatology International, Journal Year: 2025, Volume and Issue: unknown

Published: April 14, 2025

Language: Английский

Citations

1
Combining gut microbiota modulation and immunotherapy: A promising approach for treating microsatellite stable colorectal cancer DOI

Yujie Chang,

Min Long,

Hanguo Shan

et al.

Critical Reviews in Oncology/Hematology, Journal Year: 2025, Volume and Issue: 208, P. 104629 - 104629

Published: Jan. 27, 2025

Language: Английский

Citations

0
Huaier enhances the antitumor effects of CDK 4/6 inhibitor by remodeling the immune microenvironment and gut microbiota in breast cancer DOI
Yifei Wang, Wang Xiaolong, Wenhao Li

et al.

Journal of Ethnopharmacology, Journal Year: 2025, Volume and Issue: unknown, P. 119723 - 119723

Published: April 1, 2025

Language: Английский

Citations

0
Effect of Gut Dysbiosis on Onset of GI Cancer DOI Open Access
Seema Kumari, Mundla Srilatha, Ganji Purnachandra Nagaraju

et al.

Cancers, Journal Year: 2024, Volume and Issue: 17(1), P. 90 - 90

Published: Dec. 30, 2024

Dysbiosis in the gut microbiota plays a significant role GI cancer development by influencing immune function and disrupting metabolic functions. can drive carcinogenesis through pathways like dysregulation release of carcinogenic metabolites, altered metabolism, genetic instability, pro-inflammatory signalling, contributing to initiation progression. Helicobacter pylori infection genotoxins released from dysbiosis, lifestyle dietary habits are other factors that contribute development. Emerging diagnostic therapeutic approaches show promise colorectal treatment, including multitarget faecal immunochemical test (mtFIT), standard FIT, transplantation (FMT) combined with PD-1 inhibitors. We used search engine databases PubMed, Scopus, Web Science. This review discusses dysbiosis onset explores strategies such as FMT, probiotics, prebiotics enhance response improve therapy outcomes.

Language: Английский

Citations

0